Surescripts acquires ActiveRADAR ActiveRADAR offers evidence-based, formulary-specific and medically accepted use-specific therapeutic alternatives. Alembic unveils 2 genericsAlembic is launching generic Robinul and generic Adrucil. U.S. District Court dismisses Norwich’s lawsuit against the FDA over generic Xifaxan Norwich asked the District Court to direct the FDA in granting immediate approval for generic Xifaxan (rifaximin) 550 mg. FDA approves Amgen’s Wezlana biosimilar Wezlana is used to treat multiple inflammatory diseases. Theravance, Mylan settle patent litigation with Teva over Yupelri Teva has been granted a royalty-free, non-exclusive license to market generic Yupelri in the United States on or after April 23, 2039. Alembic debuts 2 generics Alembic is introducing generic chlorpromazine hydrochloride tablets and generic Combigan. Somerset intros generic calcium gluconate Calcium gluconate is an essential medicine used in the treatment of acute symptomatic hypocalcemia in pediatric and adult patients. Aurobindo receives FDA nod for generic Uloric Febuxostat tablets are indicated for the chronic management of hyperuricemia in patients with gout. Camber Pharmaceuticals launches generic Inspra Eplerenone tablets are indicated for improving survival of stable patients with symptomatic heart failure with reduced ejection fraction after an acute myocardial infarction. Roche settles patent lawsuit against Biogen over Actemra biosimilar Roche's lawsuit, filed in July, said the biosimilar would infringe several patents related to the manufacture and use of its biologic drug. First Previous 40 41 42 43 44 Next Last
